Moreover, XPO1/CRM1 overexpression has been associated with a negative prognosis in various cancers such as multiple myeloma, acute myeloid leukemia, malignant gliomas, pancreatic cancer and soft tissue sarcomas [1, 6–10] Exportin-1 has then become an attractive therapeutic target in cancer drug development by dysregulating the conveyance of regulatory proteins and thus leading to intranuclear accumulation of tumor suppressor proteins and inhibiting tumor growth. This evidence concerns the gene XPO1 and cancer.